GSA Capital Partners LLP Boosts Position in Zynex, Inc. (NASDAQ:ZYXI)

GSA Capital Partners LLP increased its position in Zynex, Inc. (NASDAQ:ZYXI) by 72.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 79,930 shares of the company’s stock after purchasing an additional 33,649 shares during the period. GSA Capital Partners LLP owned 0.25% of Zynex worth $652,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Investment Partners Asset Management Inc. purchased a new stake in Zynex in the third quarter worth $96,000. Hsbc Holdings PLC purchased a new stake in Zynex in the second quarter worth $113,000. Quest Partners LLC grew its stake in Zynex by 646.7% in the second quarter. Quest Partners LLC now owns 12,926 shares of the company’s stock worth $120,000 after purchasing an additional 11,195 shares during the period. State Board of Administration of Florida Retirement System purchased a new stake in Zynex in the first quarter worth $137,000. Finally, Principal Financial Group Inc. grew its stake in Zynex by 10.4% in the second quarter. Principal Financial Group Inc. now owns 19,525 shares of the company’s stock worth $182,000 after purchasing an additional 1,846 shares during the period. 29.68% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zynex

In other Zynex news, CFO Daniel J. Moorhead sold 10,000 shares of the stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $8.59, for a total value of $85,900.00. Following the transaction, the chief financial officer now owns 44,878 shares of the company’s stock, valued at approximately $385,502.02. This represents a 18.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders have sold 24,000 shares of company stock valued at $208,440. 52.13% of the stock is owned by company insiders.

Zynex Trading Up 0.1 %

Shares of NASDAQ:ZYXI opened at $7.81 on Tuesday. The company has a market cap of $248.75 million, a P/E ratio of 52.00 and a beta of 0.53. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.94 and a quick ratio of 3.15. Zynex, Inc. has a 1 year low of $7.15 and a 1 year high of $13.77. The stock’s fifty day moving average price is $8.23 and its 200-day moving average price is $8.85.

Zynex (NASDAQ:ZYXI) last posted its earnings results on Thursday, October 24th. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. Zynex had a return on equity of 13.05% and a net margin of 2.49%. The company had revenue of $49.97 million for the quarter, compared to the consensus estimate of $50.83 million. During the same quarter in the prior year, the company earned $0.10 earnings per share. Zynex’s revenue was up .1% on a year-over-year basis. Sell-side analysts expect that Zynex, Inc. will post 0.2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Royal Bank of Canada cut their target price on Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. HC Wainwright increased their target price on Zynex from $16.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, October 25th.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.